Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Arachidonic Acid and Valproic Acid

Research Papers that Mention the Interaction

BACKGROUND … of chronic valproate (VPA) … arachidonic acid (AA) turnover in brain phospholipids of unanesthetized rats has been ascribed to its inhibition of acyl-CoA synthetase (Acsl)-mediated activation … AA to AA-CoA. Our aim was to identify a rat Acsl isoenzyme that could be inhibited by VPA in vitro.
Biochimica et biophysica acta  •  2011  |  View Paper
It is based on evidence that chronic administration of lithium, carbamazepine, sodium valproate , or lamotrigine to rats downregulated AA turnover in brain phospholipids, formation of prostaglandin E(2), and/or expression of AA cascade enzymes, including cytosolic phospholipase A(2), cyclooxygenase-2 and/or acyl-CoA synthetase.
Brain Research Reviews  •  2009  |  View Paper
In shock blood, incubation with VPA significantly reduced collagen-(P = 0.050), arachidonic acid-(P = 0.005), and adenosine diphosphate-(P = 0.023) induced platelet aggregation.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis  •  2017  |  View Paper
In vitro studies … of these, valproic acid (VPA), which …, reduces AA turnover by inhibiting the brain long-chain acyl-CoA synthetase (Acsl)4 mediated acylation of AA to AA-CoA. … whether non-teratogenic VPA analogues might also inhibit Acsl4 catalyzed acylation, and thus have a potential anti-BD action.
Biochimica et biophysica acta  •  2013  |  View Paper
We hypothesized that valproate (VPA), with mood-stabilizing properties, would also reduce D(2)-like-mediated signaling via AA.
Neuropharmacology  •  2011  |  View Paper
VPA shares many cellular and molecular targets with lithium, including reducing arachidonic acid turnover in rat brain phospholipids and cyclooxygenase-2 (COX-2) protein level and activity in rat brain.
Bipolar disorders  •  2007  |  View Paper
RationaleIt has been reported that each of three drugs effective in treating bipolar disorder (lithium, carbamazepine, and valproate ) decreases the turnover of arachidonic acid (AA, 20:4n-6) in brain phospholipids of the awake rat.
Psychopharmacology  •  2005  |  View Paper
Because chronic lithium, carbamazepine and valproate decrease the turnover of arachidonic acid (AA) but not docosahexaenoic acid (DHA) in brain phospholipids of the awake rat, we tested if topiramate would produce similar results.
Neurochemical Research  •  2005  |  View Paper
The study supports the hypothesis that valproic acid acts in bipolar disorder by reducing the brain arachidonic acid cascade , by inhibiting arachidonoyl–CoA formation.
Psychopharmacology  •  2005  |  View Paper
Based on evidence that lithium and valproate , other mood stabilizers, reduce brain arachidonic acid turnover and its conversion via cyclooxygenase to prostaglandin E(2) in rat brain, one possibility is that carbamazepine also targets the arachidonic acid cascade.
Biological Psychiatry  •  2004  |  View Paper
Show More